Kronos Bio Stock Today
| KRON Stock | USD 0.87 0.01 1.16% |
Performance0 of 100
| Odds Of DistressOver 82
|
Kronos Bio is selling at 0.87 as of the 22nd of November 2024; that is 1.16 percent increase since the beginning of the trading day. The stock's open price was 0.86. Kronos Bio has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Kronos Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of October 2020 | Category Healthcare | Classification Health Care |
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company was incorporated in 2017 and is headquartered in San Mateo, California. Kronos Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 60.34 M outstanding shares of which 527.68 K shares are now shorted by private and institutional investors with about 8.81 trading days to cover. More on Kronos Bio
Moving together with Kronos Stock
Moving against Kronos Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Kronos Stock Highlights
| CEO President | Norbert Bischofberger | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsKronos Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Kronos Bio's financial leverage. It provides some insight into what part of Kronos Bio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Kronos Bio (KRON) is traded on NASDAQ Exchange in USA. It is located in 1300 South El Camino Real, San Mateo, CA, United States, 94402 and employs 58 people. Kronos Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 51.89 M. Kronos Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 60.34 M outstanding shares of which 527.68 K shares are now shorted by private and institutional investors with about 8.81 trading days to cover.
Kronos Bio currently holds about 267.89 M in cash with (78.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Kronos Bio Probability Of Bankruptcy
Ownership AllocationKronos Bio maintains a total of 60.34 Million outstanding shares. Kronos Bio holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Kronos Ownership Details
Kronos Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Acuitas Investments, Llc | 2024-06-30 | 443.5 K | |
| Jacobs Levy Equity Management, Inc. | 2024-06-30 | 440.7 K | |
| Hpm Partners Llc | 2024-06-30 | 410.8 K | |
| Choate Investment Advisors | 2024-09-30 | 308.7 K | |
| Gentrust, Llc | 2024-09-30 | 295.2 K | |
| Citadel Advisors Llc | 2024-06-30 | 227.9 K | |
| Cm Management, Llc | 2024-09-30 | 200 K | |
| Bridgeway Capital Management, Llc | 2024-06-30 | 199.7 K | |
| Two Sigma Advisers, Llc | 2024-06-30 | 194.4 K | |
| Vida Ventures Advisors, Llc | 2024-09-30 | 2.8 M | |
| Vanguard Group Inc | 2024-09-30 | 1.9 M |
Kronos Bio Historical Income Statement
Kronos Stock Against Markets
Kronos Bio Corporate Management
| Christopher Dinsmore | Strategic Advisor | Profile | |
| Stephanie Yao | Exec Communications | Profile | |
| Barbara JD | Strategic Advisor | Profile | |
| Marni Kottle | Sr Relations | Profile | |
| Rocio Hoyos | Senior Management | Profile | |
| Joshua Kazam | CoFounder Director | Profile | |
| Sandra Gardiner | Interim Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kronos Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.43) | Revenue Per Share 0.143 | Quarterly Revenue Growth 0.442 | Return On Assets (0.28) | Return On Equity (0.63) |
The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.